Last week, CLS Holdings USA, Inc. (OTCQB: CLSH) (CSE: CLSH) released financial results from June that showed impressive growth and improvements in several important areas. We believe the US cannabis operator is flying under the radar and will continue to monitor how it executes on a planned expansion.
At current levels, we believe that CLS has a compelling valuation when analyzed by several profitability metrics. Based on the June numbers, we believe the diversified cannabis company is trading to a steep discount when compared to its peers and have issued an update on the business.
A Diversified Opportunity that is Capturing Additional Market Share
CLS is a diversified cannabis company that operates as Cannabis Life Science. The company operates as an integrated cannabis producer and retailer through its City Trees and Oasis Cannabis subsidiaries in Nevada.
In 2015, Oasis Cannabis opened its first cannabis dispensary in Las Vegas and has been recognized as one of the top retailers in Nevada. The location is strategically located near the Las Vegas Strip and offers customers access to its delivery service.
In 2017, City Trees was founded and is a Nevada-based cannabis cultivation, production, and distribution company. During that year, CLS started to sell City Trees branded wholesale cannabis products (cannabis concentrates and infused products) in Nevada and we are bullish on the growth prospects that are associated with the brand.
Reports Strong Growth in June
In June, CLS reported to have generated $1.8 million of revenue and a 56.2% gross margin. During the month, the company’s City Trees brand announced an endorsement agreement with UFC welterweight fighter, Sasha Palatnikov. We are favorable on how the business has grown and believe that our readers should be aware of CLS.
When compared to June of 2020, CLS record more than 60% of